Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) EBITDA Margin: 2011-2023

Historic EBITDA Margin for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Sep 2025 value amounting to 61.84%.

  • Ironwood Pharmaceuticals' EBITDA Margin rose 3385.00% to 61.84% in Q3 2025 from the same period last year, while for Sep 2025 it was 36.34%, marking a year-over-year increase of 1012.00%. This contributed to the annual value of 26.50% for FY2024, which is 24004.00% up from last year.
  • Per Ironwood Pharmaceuticals' latest filing, its EBITDA Margin stood at 61.84% for Q3 2025, which was up 16.31% from 53.17% recorded in Q2 2025.
  • Over the past 5 years, Ironwood Pharmaceuticals' EBITDA Margin peaked at 376.14% during Q2 2021, and registered a low of -1,014.58% during Q2 2023.
  • In the last 3 years, Ironwood Pharmaceuticals' EBITDA Margin had a median value of 31.98% in 2023 and averaged -68.66%.
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' EBITDA Margin slumped by 105,272bps in 2023, and later soared by 104,104bps in 2024.
  • Quarterly analysis of 5 years shows Ironwood Pharmaceuticals' EBITDA Margin stood at 35.32% in 2021, then skyrocketed by 1,026bps to 45.59% in 2022, then slumped by 1,361bps to 31.98% in 2023, then soared by 280bps to 34.78% in 2024, then skyrocketed by 3,385bps to 61.84% in 2025.
  • Its EBITDA Margin was 61.84% in Q3 2025, compared to 53.17% in Q2 2025 and -70.75% in Q1 2025.